General requirements for marketing authorization transfers in Thailand, Malaysia, Singapore, Indonesia and Philippines
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 2
Abstract
The review article is only for brief idea about the Marketing Authorization Transfers in few of ASEAN region. Whatever the data here I have been provided is according to my knowledge and study depends on healthy authorities/regulatory authorities sometimes requirements also may change. A Marketing Authorization Transfer is may be necessary to a company selling their product rights to another company it’s like acquisition. In Order to transfer any kind of Pharmaceutical Products in ASEAN region from one MAH to other MAH that particular product must have a Marketing Authorization Transfer issued by the competent health/Regulatory Authority. This MAT is issued to a legal entity called MAT. It is a procedure by which the MA is transferred from the Old MAH to New MAH which is a different legal entity. The MA holder is completing responsibility for the life of the pharmaceutical product including all technical development and further alterations. The MAT process outcomes in the original MAH rights and responsibilities concerning the specific pharmaceutical product to be transferred to the New MAH on a specific date on which the transfer is stimulated. According to dossier all the parameters would be present. The expiry date is same and therefore, if applicable, the date by which it has to be renewed in order to remain legal. If any obligations are applicable (post authorization): PSUR, follow-up measures and special commitments
Authors and Affiliations
Prathyusha Jeeva, Jyothshna Devi Katamreddy
Keywords
Related Articles
- EP ID EP329330
- DOI 10.22270/ijdra.v6i2.244
- Views 106
- Downloads 0
Comparative study of the harmonization of pharmaceutical regulations in the western and central sub-regions of Africa
The harmonization of pharmaceutical regulations in Africa aims to offer States a coherent body of texts and practices by combining limited resources. The objective of this study was to describe policies to harmonize phar...
CURRENT REGULATION OF MEDICAL GASES IN INDIA AND FUTURE ASPECTS
Generally medical gases are administered or supplied directly to the patients. They should be manufactured and transferred with the highest quality possible as per standards and limits decided by the different regulatory...
BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower d...
FORMULATION AND DEVELOPMENT OF KETOPROFEN BILAYER TABLETS
Aim of present research work was formulation and development of bilayer tablets of Ketoprofen to reduce the side effects of Ketoprofen and to improve the therapeutic benefits and patients’ compliance to treatment. Bi-lay...
FORMULATION AND EVALUATION OF NANOSUSPENSION OF ROSUVASTATIN CALCIUM
Poor water solubility and slow dissolution rate are issues for majority of upcoming and existing biologically active compounds. The aim of present work was to increase the dissolution rate of Rosuvastatin Calcium, a poor...